Blog
RSS FeedPosted by Michael Wonder on 04 Jul 2022
TLV reconsiders Orkambi's subsidy
4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...
Posted by Michael Wonder on 30 Jun 2022
Review into COVID-19 vaccine and treatment purchases
30 June 2022 - The Australian Government is undertaking an independent review of Australia’s vaccine and treatment procurements, led by former ...
Posted by Michael Wonder on 23 Jun 2022
Expediency versus efficacy: re-examining the FDA’s accelerated drug approval process
23 June 2022 - It was precisely 30 years ago, in 1992, that the FDA established the accelerated approval program ...
Posted by Michael Wonder on 20 Jun 2022
HIRA reviews reimbursing antidiabetic combo therapies
15 June 2022 - HIRA has been analysing how new reimbursements for anti-diabetic combination therapies mixing oral SGLT-2 and DPP-4 ...
Posted by Michael Wonder on 13 Jun 2022
Medicines Australia moves quickly to put HTA system reform high on new Government’s agenda
10 June 2022 - Medicines Australia has moved quickly to ensure that major reform of Australia’s health technology assessment system ...
Posted by Michael Wonder on 02 Jun 2022
Hope for change after PHARMAC independent review
2 June 2022 - A woman who had her bowel removed while she waited for drugs that would probably have ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 01 Jun 2022
Health Minister urges PHARMAC to focus on equity and collaboration
1 June 2022 - PHARMAC will need to engage more with other parts of the health system and the public - ...
Posted by Michael Wonder on 01 Jun 2022
Government response to independent PHARMAC review
1 June 2022 - The Government has released its response to the recommendations of the final report of the independent ...
Posted by Michael Wonder on 29 May 2022
Accelerated approval: unfulfilled promises for FDA’s expedited review program
27 May 2022 - As practicing physicians, approval by the U.S. FDA reassures us that the treatments we prescribe our patients ...
Posted by Michael Wonder on 28 May 2022
Where is the PHARMAC review?
28 May 2022 - “It has been three months to the day since the Minister received the PHARMAC review, why ...
Posted by Michael Wonder on 25 May 2022
Review of discount rate in the PBAC Guidelines
25 May 2022 - The Commonwealth has entered into a new Strategic Agreement in relation to reimbursement, health technology assessment ...
Posted by Michael Wonder on 19 May 2022
Medicines Australia puts spotlight on reform priority for the next Government
20 May 2022 - Medicines Australia has set the scene for major health reform by the next Government by alerting ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 May 2022
Discount rate adjustment for the health of future generations
17 May 2022 - Medicines Australia has released a video detailing the need for Australia to adjust its discount rate ...